# Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy

> **NCT03578081** · PHASE3 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 690 (actual)

## Conditions studied

- Malignant Neoplasm

## Interventions

- **DRUG:** Palonosetron Hydrochloride
- **DRUG:** Ondansetron Hydrochloride
- **DRUG:** Dexamethasone
- **DRUG:** Fosaprepitant Dimeglumine
- **DRUG:** Olanzapine
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03578081
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-11-20
- **Primary completion:** 2021-11-08
- **Final completion:** 2023-05-01
- **Target enrollment:** 690 (ACTUAL)
- **Last updated:** 2025-04-06

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03578081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03578081, "Olanzapine With or Without Fosaprepitant Dimeglumine in Preventing Chemotherapy Induced Nausea and Vomiting in Cancer Patients Receiving Highly Emetogenic Chemotherapy". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03578081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*